Skip to main content

Iovance Biotherapeutics, Inc. (IOVA) Stock

Iovance Biotherapeutics, Inc. Stock Details, Movements and Public Alerts

Stock Details

Iovance Biotherapeutics, Inc. (IOVA), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NGM.Currently, the stock is trading at $4.04. Over the past 52 weeks, it has ranged between $1.64 and $5.63. This places the current price at 71.8% of its 52-week high and 146.3% above its 52-week low. Recent trading volume was recorded at 14,675,087. The 14-day Relative Strength Index (RSI) stands at 78.94, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $2.70 by 49.63%. Similarly, it is above its 200-day moving average of $2.34 by 72.65%. The MACD histogram is 0.14, indicating bullish momentum (MACD Line: 0.30, Signal Line: 0.16).

52-Week Range

$5.63 - $1.64

-28.24% from high · +146.34% from low

Avg Daily Volume

15,031,673

20-day average

100-day avg: 14,394,286

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-16.43

Price to Book

2.33

EV/EBITDA

-3.82

EPS (TTM)

-$1.09

Price to Sales

6.19

Beta

0.74

Less volatile than market

Q:How is IOVA valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is IOVA's risk profile compared to the market?
With a beta of 0.74, Iovance Biotherapeutics, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 2.33 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-148.38%

Operating Margin

-84.66%

EBITDA

$-362,273,984

Return on Equity

-55.50%

Return on Assets

-27.30%

Revenue Growth (YoY)

17.70%

Q:How profitable and efficient is IOVA's business model?
Iovance Biotherapeutics, Inc. achieves a profit margin of -148.38%, meaning it retains $-148.38 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -84.66% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -55.50% and ROA at -27.30%, the company achieves moderate returns on invested capital.
Q:What are IOVA's recent growth trends?
Iovance Biotherapeutics, Inc.'s revenue grew by 17.70% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$1.6B

Revenue (TTM)

$263.50M

Revenue/Share (TTM)

$0.74

Shares Outstanding

411.96M

Book Value/Share

$1.70

Asset Type

EQUITY

Q:What is IOVA's market capitalization and position?
Iovance Biotherapeutics, Inc. has a market capitalization of $1.6B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 411.96M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does IOVA's price compare to its book value?
Iovance Biotherapeutics, Inc.'s book value per share is $1.70, while the current stock price is $4.04, resulting in a price-to-book (P/B) ratio of 2.38. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$9.00

122.77% upside potential

Analyst Recommendations

Strong Buy

1

Buy

6

Hold

4

Sell

1

Strong Sell

0

Q:How reliable are analyst predictions for IOVA?
12 analysts cover IOVA with 58% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $9.00 implies 122.8% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on IOVA?
Current analyst recommendations:1 Strong Buy, 6 Buy, 4 Hold, 1 Sell, 0The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 15, 2026, 02:48 AM

Technical Indicators

RSI (14-day)

78.94

Overbought

50-Day Moving Average

$2.70

49.63% above MA-50

200-Day Moving Average

$2.34

72.65% above MA-200

MACD Line

0.30

MACD Signal

0.16

MACD Histogram

0.14

Bullish

Q:What does IOVA's RSI value tell investors?
The RSI (Relative Strength Index) for IOVA is currently 78.94, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret IOVA's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.30 above the signal line at 0.16, with histogram at 0.14. This bullish crossover suggests upward momentum is building. The 50-day MA ($2.70) is above the 200-day MA ($2.34), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Mar 1, 2026, 12:40 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for IOVA and get notified when the price changes.

Stay Ahead of the Market with Iovance Biotherapeutics, Inc. Alerts

Set up price alerts for Iovance Biotherapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.